mBio · 2022 · 11 citations · 18 references
Life SciencesImmunologyInfectious DiseasesImmunology Of Infectious DiseasesImmunopharmacologyImmunotherapyAntiviral TherapyImmunogenicity Of Therapeutic AntibodiesMonoclonal Antibody TherapyTherapeutic Antibody DevelopmentAntibodiesAntibody Therapeutic EfficacyAntibody-mediated Viral NeutralizationImmunogenicity Of Biologic AgentsNeutralizing Antibody PrevalenceSars-cov-2 Antiviral TherapySars-cov-2 Infection
analysis demonstrates that there is a subset of hospitalized seropositive patients with inadequate SARS-CoV-2-neutralizing antibodies (i.e., those who were negative or borderline for neutralizing antibodies) who may still benefit from CAS+IMD treatment if infected with a susceptible SARS-CoV-2 variant. Therefore, utilizing serostatus alone to guide treatment decisions for patients with COVID-19 may fail to identify those seropositive patients who could benefit from anti-SARS-CoV-2 monoclonal antibody therapies known to be effective against circulating strains, dependent upon how effectively their endogenous antibodies neutralize SARS-CoV-2.
18
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Johanna K. Hansen, Alina Baum, Kristen E. Pascal et al. · Science · 2020 · 1.4K citations · Full text